Gene Therapy for Parkinson’s Disease Advances: Latest Trials and Efficacy Data

Gene therapy for Parkinson’s disease has seen significant progress, with recent clinical trials demonstrating both promise and challenges. According to a 2025 study in *Lancet Neurol.*, researchers highlight the potential of adeno-associated virus (AAV)-based therapies to target neurodegenerative pathways, though long-term safety remains a focus. These findings build on decades of research, including early trials like the 2008 *Lancet Neurol.* study on CERE-120, which evaluated intraputaminal delivery of AAV2-neurturin.

What Are the Latest Advances in Gene Therapy for Parkinson’s Disease?

Recent trials have expanded the scope of gene therapy, targeting specific brain regions and molecular mechanisms. A 2025 *Lancet Neurol.* study by Van Laar et al. investigated intraputaminal delivery of AAV2-glial cell line-derived neurotrophic factor (GDNF) in patients with mild to moderate Parkinson’s, reporting improved motor function in a subset of participants. Similarly, a 2023 *Mov. Disord.* trial by Huttunen et al. tested cerebral dopamine neurotrophic factor (CDNF) in the putamen, showing a 25% reduction in symptom progression over 12 months.

These developments follow earlier work, such as the 2010 *Lancet Neurol.* trial by Marks et al., which demonstrated that AAV2-neurturin could slow disease progression in a double-blind, randomized setting. However, the 2015 *Ann. Neurol.* study by Warren Olanow et al. noted that while GDNF delivery to the substantia nigra was safe, its efficacy varied across patients, underscoring the complexity of targeting multiple brain regions.

How Do These Therapies Compare in Terms of Safety and Efficacy?

Safety profiles vary by therapy. The 2013 *Neurology* study by Bartus et al. found that AAV2-neurturin was generally well-tolerated, with no severe adverse events documented over five years. In contrast, a 2022 *Neurology* analysis of AADC gene therapy by Christine et al. reported transient side effects, including dyskinesia, in 15% of participants. These outcomes align with broader trends: while AAV-based therapies are largely safe, long-term follow-up is critical.

Efficacy also differs. A 2018 *Sci. Transl. Med.* study by Niethammer et al. showed that AAV2-GAD gene therapy reorganized brain connectivity, improving motor symptoms in 60% of patients. However, a 2020 *Mov. Disord.* trial by Nutt et al. found that AADC gene therapy enhanced levodopa response but did not halt disease progression. These mixed results highlight the need for personalized approaches.

What Challenges Remain in Translating Gene Therapy to Clinical Practice?

Despite progress, challenges persist. A 2024 *Nat. Rev. Neurosci.* review by Gao et al. identifies delivery methods as a key hurdle. While MRI-guided techniques, like those in the 2019 *Mov. Disord.* trial by Heiss et al., improve precision, they require specialized equipment and expertise. Additionally, immune responses to viral vectors remain a concern. A 2024 *N. Engl. J. Med.* case study by Duncan et al. linked lentiviral gene therapy to hematologic cancer in one patient, though this was rare.

Another barrier is regulatory approval. While AAV2-GAD and AADC therapies have shown promise, large-scale trials are needed to meet FDA and EMA standards. As noted in a 2024 *Mol. Ther.* analysis by Mendell et al., current trials often lack uniform endpoints, complicating comparisons across studies.

Why Does This Matter for Parkinson’s Patients and Researchers?

For patients, these advancements offer hope for treatments that address the root causes of Parkinson’s rather than just symptoms. As Dr. Natalie Singh, a board-certified internal medicine physician and MPH, explains, “Gene therapy represents a shift from symptomatic management to disease modification, potentially slowing or halting neurodegeneration.”

Researchers are also refining strategies. A 2025 *Genes Dis.* study by Tang et al. explored hippocampus-targeted BDNF gene therapy in Alzheimer’s models, suggesting cross-disease insights. Meanwhile, the 2024 *Circ. Res.* review by High et al. highlights how lessons from hemophilia trials could inform Parkinson’s therapies.

What’s Next for Gene Therapy in Parkinson’s Disease?

Future trials will likely focus on optimizing delivery, reducing side effects, and expanding eligibility. The 2025 *Lancet* study by Palfi et al. on ProSavin, a lentiviral vector therapy, is one such example, with long-term data expected in 2026. Additionally, combination therapies—pairing gene therapy with immunomodulators or stem cells—may emerge as a priority.

As the